RXRX

Recursion Pharmaceuticals Inc

Apr 01 • 04:00PM ET

3.06

-0.01 -0.33 %

Healthcare • Biotechnology • USA • NASD

Peers: ABCL SDGR DNLI NBIX CRSP BEAM NTLA EDIT VRTX RGNX

| Held by: ARKK VTI XBI VB ARKG IWM VBK VXF IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-1.48	Insider Own	11.88%	Shs Outstand	521.83M	Perf Week	-3.47%
Market Cap	1.62B	Forward P/E	-	EPS next Y	-0.87	Insider Trans	-2.46%	Shs Float	465.52M	Perf Month	-13.56%
Enterprise Value	946.69M	PEG	-	EPS next Q	-0.26	Inst Own	55.92%	Short Float	37.41%	Perf Quarter	-25.55%
Income	-644.76M	P/S	21.65	EPS this Y	31.51%	Inst Trans	2.39%	Short Ratio	9.21	Perf Half Y	-37.30%
Sales	74.68M	P/B	1.43	EPS next Y	11.93%	ROA	-43.32%	Short Interest	174.14M	Perf YTD	-25.18%
Book/sh	2.14	P/C	2.16	EPS next 5Y	32.39%	ROE	-59.54%	52W High	7.18 -57.38%	Perf Year	-39.94%
Cash/sh	1.42	P/FCF	-	EPS past 3/5Y	-1.84% -22.39%	ROIC	-54.31%	52W Low	2.80 9.29%	Perf 3Y	-54.12%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	23.30% 79.91%	Gross Margin	-61.96%	Volatility	5.76% 5.57%	Perf 5Y	-
Dividend TTM	-	EV/Sales	12.68	EPS Y/Y TTM	10.74%	Oper. Margin	-867.87%	ATR (14)	0.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.50	Sales Y/Y TTM	26.92%	Profit Margin	-863.35%	RSI (14)	38.19	Recom	2.43
Dividend Gr. 3/5Y	- -	Current Ratio	5.50	EPS Q/Q	61.44%	SMA20	-6.55%	Beta	1.01	Target Price	6.00
Payout	-	Debt/Eq	0.07	Sales Q/Q	681.74%	SMA50	-16.57%	Rel Volume	0.57	Prev Close	3.07
Employees	600	LT Debt/Eq	0.05	Earnings	Feb 25 BMO	SMA200	-35.07%	Avg Volume	18.91M	Price	3.06
IPO	Apr 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.33% 44.04%	Trades		Volume	10,803,180	Change	-0.33%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-25	Upgrade	JP Morgan	Neutral → Overweight	$11
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight	$5
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Mar-25-26 07:59AM	Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer (GlobeNewswire)
Mar-10-26 05:45PM	Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
Mar-09-26 08:11PM	What Makes Recursion Pharmaceuticals (RXRX) So Attractive (Insider Monkey)
Mar-06-26 12:01PM	BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating (Insider Monkey)
Feb-27-26 09:49AM	Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
09:37AM	Loading…
09:37AM	Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Feb-26-26 08:00PM	Recursion Pharmaceuticals Inc (RXRX) Q4 2025 Earnings Call Highlights: Strategic Milestones and ... (GuruFocus.com)
02:27PM	Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M (Insider Monkey)
10:08AM	Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:52AM	ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
Feb-25-26 05:25PM	Recursion Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) +6.80%
12:37PM	Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
12:15PM	Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
10:54AM	What's Behind The Jump In Recursion Pharmaceuticals Stock? (Benzinga)
10:21AM	RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up (Zacks)
06:38AM	Loading…
06:38AM	Recursion Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 03:52PM	ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025 (Benzinga)
07:25AM	Recursion Pharmaceuticals Inc (RXRX) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-23-26 02:47PM	Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts (Insider Monkey)
10:33AM	Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week (Benzinga)
09:07AM	What's in Store for These 5 Medical Companies This Earnings Season? (Zacks)
08:00AM	Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC (GlobeNewswire)
07:55AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-26 05:45PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks) -8.06%
10:01AM	Cathie Wood Pours $24 Million to This AI Software Stock (GuruFocus.com)
Feb-19-26 05:10PM	Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates (Zacks) +5.38%
04:47PM	Nvidia Dumped Recursion Pharmaceuticals Stock. Should You? (Barchart)
11:14AM	NVIDIAs 13F Bombshell: A New AI Power Trio Emerges (MarketBeat)
05:27AM	Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. (Barrons.com)
05:50PM	Loading…
Feb-18-26 05:50PM	Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider (Zacks)
04:40PM	Applied Digital, WeRide Stocks Drop. Blame Nvidia. (Barrons.com)
02:07PM	Recursion Pharmaceuticals Stock Drops: What's Behind It? (Benzinga)
01:21PM	Nvidia Sold Its Stakes in These Firms. The Stocks Are Sliding. (Investopedia)
09:37AM	Applied Digital, WeRide Stocks Drop After Nvidia Sells Holdings (The Wall Street Journal)
08:30AM	Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25 (GlobeNewswire)
05:43AM	Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia. (Barrons.com)
Feb-17-26 04:58PM	Cathie Wood Buys COIN, HOOD (GuruFocus.com)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-12-26 10:00AM	2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off (24/7 Wall St.)
07:59AM	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules (GlobeNewswire)
Feb-10-26 05:45PM	Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Feb-04-26 05:50PM	Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -8.72%
Jan-29-26 05:50PM	Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors (Zacks)
09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
06:15AM	Forget 2025: These 2 Growth Stocks Could Soar in 2026 (Motley Fool)
Jan-28-26 09:21PM	Can This Beaten-Down AI Stock Bounce Back in 2026? (Motley Fool)
Jan-24-26 03:35AM	Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? (Insider Monkey)
Jan-23-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jan-20-26 10:14AM	Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory (Insider Monkey) -5.78%
Jan-18-26 12:30PM	JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects (Insider Monkey)
Jan-16-26 05:05PM	2 AI Stocks to Buy in 2026, and 1 to Avoid (Motley Fool) -5.78%
Jan-15-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Jan-08-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jan-07-26 08:20PM	Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates (Insider Monkey) +6.81%
Jan-06-26 07:59AM	Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 03:22PM	Getty Images, Torm, and More Stocks See Action From Activist Investors (Barrons.com)
09:10AM	JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline (Insider Monkey)
Jan-01-26 07:45AM	Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. (Motley Fool)
Dec-30-25 11:49PM	Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) (Insider Monkey)
Dec-29-25 11:42AM	Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP (Insider Monkey)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Dec-28-25 12:46PM	Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform (Insider Monkey)
Dec-24-25 09:00AM	Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? (Barchart)
Dec-21-25 07:40AM	Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? (Insider Monkey)
Dec-19-25 07:33AM	Cathie Wood Keeps Dumping Tesla Stock -- Here is Why (GuruFocus.com)
Dec-18-25 05:24AM	Why Recursion Pharmaceuticals, Inc. (RXRX)'s Upside Case Hasn't Fully Convinced Yet (Insider Monkey) -5.13%
Dec-17-25 05:27PM	Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday (Motley Fool) +11.43%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire)
Dec-08-25 05:30PM	Why Recursion Pharamaceuticals Topped the Market Today (Motley Fool)
07:30AM	Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks (GlobeNewswire)
12:32AM	Jim Cramer on Recursion: "It Is so Low That It Comes in Under the Category of Speculative" (Insider Monkey)
Dec-05-25 11:30AM	Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 09:04PM	Lightning Round: Recursion Pharmaceuticals and NuScale Power (CNBC TV) +5.58%
06:05AM	10 AI Stocks Worth Buying Right Now (Motley Fool)
Dec-01-25 08:30AM	Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 (GlobeNewswire) -5.83%
Nov-28-25 06:45AM	Cathie Wood Dumps Millions in Tesla -- Loads Up on Coinbase After Sharp Swings (GuruFocus.com)
Nov-24-25 08:53AM	Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? (Motley Fool)
Nov-22-25 10:11AM	Recursion (RXRX) Jumps 8% on Bargain-Hunting (Insider Monkey)
Nov-21-25 05:02AM	Is Recursion Pharmaceuticals Inc. (RXRX) One of the Best Mid Cap Stocks to Buy According to Hedge Funds? (Insider Monkey) +8.31%
Nov-19-25 08:13AM	Is Recursion Pharmaceuticals a Meme Stock? (Motley Fool)
Nov-12-25 09:45AM	Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock (Motley Fool)
Nov-06-25 09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks) -6.85%
Nov-05-25 07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
06:34AM	Recursion Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
06:28AM	Recursion Announces CEO Transition Plan to Drive Next Phase of Growth (GlobeNewswire)
Nov-04-25 08:45AM	3 Things Investors Need to Know About Recursion Pharmaceuticals (Motley Fool) -8.09%
08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 11:19AM	Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-31-25 06:15AM	Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? (Motley Fool)
Oct-29-25 10:00AM	Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors (Zacks) -6.19%
08:00AM	Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th (GlobeNewswire)
Oct-22-25 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks) -5.89%
08:56AM	Jim Cramer on Recursion Pharmaceuticals: "Now, It's a Meme Stock" (Insider Monkey)
Oct-21-25 12:56PM	Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings (Insider Monkey) -8.53%
10:00AM	Up 25% in 1 Month, Is This Stock a Buy? (Motley Fool)
Oct-19-25 04:00AM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
Oct-16-25 05:50PM	Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -6.33% -7.86%

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gibson Christopher	Director	Mar 23 '26	Sale	3.25	40,000	130,000	906,556	Mar 25 04:36 PM
Gibson Christopher	Director	Mar 23 '26	Proposed Sale	3.25	40,000	130,000		Mar 23 10:49 AM
Taylor Ben R	Chief Financial Officer	Mar 17 '26	Sale	3.39	7,956	26,971	1,180,318	Mar 18 05:52 PM
Taylor Ben R	Officer	Mar 17 '26	Proposed Sale	3.39	7,956	26,971		Mar 17 10:53 AM
Khan Najat	CEO and President	Mar 09 '26	Sale	3.35	28,298	94,660	2,262,085	Mar 11 05:41 PM
Najat Khan	Officer	Mar 09 '26	Proposed Sale	3.35	28,298	94,662		Mar 09 01:45 PM
Borgeson Blake	Director	Mar 03 '26	Sale	3.46	170,000	588,200	6,259,863	Mar 04 04:38 PM
Borgeson Blake	Director	Mar 03 '26	Proposed Sale	3.46	170,000	588,200		Mar 03 12:45 PM
Gibson Christopher	Director	Feb 19 '26	Sale	3.46	40,000	138,400	906,556	Feb 19 07:30 PM
Taylor Ben R	Chief Financial Officer	Feb 18 '26	Sale	3.08	13,426	41,352	1,195,349	Feb 19 07:30 PM
Gibson Christopher	Director	Feb 19 '26	Proposed Sale	3.46	40,000	138,400		Feb 19 10:27 AM
Taylor Ben R	Officer	Feb 18 '26	Proposed Sale	3.08	13,426	41,352		Feb 18 12:21 PM
Gibson Christopher	Director	Feb 04 '26	Sale	4.12	40,000	164,800	913,839	Feb 06 05:53 PM
Borgeson Blake	Director	Feb 03 '26	Sale	4.20	220,000	924,000	6,429,863	Feb 06 05:53 PM
Gibson Christopher	Director	Feb 04 '26	Proposed Sale	4.12	40,000	164,800		Feb 04 09:50 AM
Borgeson Blake	Director	Feb 03 '26	Proposed Sale	4.20	220,000	924,000		Feb 03 11:26 AM
Gibson Christopher	Director	Jan 20 '26	Sale	4.47	40,000	178,800	913,839	Jan 22 07:34 PM
Gibson Christopher	Director	Jan 20 '26	Proposed Sale	4.47	40,000	178,800		Jan 20 11:26 AM
Borgeson Blake	Director	Jan 06 '26	Sale	4.36	220,000	959,200	6,649,863	Jan 08 05:01 PM
Gibson Christopher	Director	Jan 05 '26	Sale	4.25	40,000	170,000	933,839	Jan 07 05:04 PM
Borgeson Blake	Director	Jan 06 '26	Proposed Sale	4.36	220,000	959,200		Jan 06 09:40 AM
Gibson Christopher	Director	Jan 05 '26	Proposed Sale	4.25	40,000	170,000		Jan 05 11:07 AM
Taylor Ben R	Chief Financial Officer	Dec 29 '25	Sale	4.18	21,383	89,381	761,550	Dec 30 07:35 PM
Khan Najat	Chief R&D Commercial Officer	Dec 22 '25	Sale	4.41	124,403	548,592	611,135	Dec 29 05:24 PM
Taylor Ben R	Officer	Dec 29 '25	Proposed Sale	4.18	21,383	89,381		Dec 29 09:41 AM
Najat Khan	Officer	Dec 22 '25	Proposed Sale	4.41	124,403	548,588		Dec 22 12:20 PM
Gibson Christopher	Chief Executive Officer	Dec 19 '25	Sale	4.50	40,000	180,000	913,839	Dec 19 05:04 PM
Gibson Christopher	Officer	Dec 19 '25	Proposed Sale	4.50	40,000	180,000		Dec 19 09:52 AM
Gibson Christopher	Chief Executive Officer	Dec 04 '25	Sale	4.63	40,000	185,200	933,839	Dec 05 07:20 PM
Borgeson Blake	Director	Dec 02 '25	Sale	4.37	220,000	961,400	6,869,863	Dec 04 04:51 PM
Gibson Christopher	Officer	Dec 04 '25	Proposed Sale	4.63	40,000	185,200		Dec 04 10:01 AM
Borgeson Blake	Director	Dec 02 '25	Proposed Sale	4.37	220,000	961,400		Dec 02 12:15 PM
Gibson Christopher	Chief Executive Officer	Nov 19 '25	Sale	4.16	40,000	166,400	913,839	Nov 19 07:37 PM
Gibson Christopher	Officer	Nov 19 '25	Proposed Sale	4.16	40,000	166,400		Nov 19 10:17 AM
Gibson Christopher	Chief Executive Officer	Nov 04 '25	Sale	5.21	40,000	208,400	974,229	Nov 06 04:23 PM
Gibson Christopher	Officer	Nov 04 '25	Proposed Sale	5.21	40,000	208,400		Nov 04 09:51 AM
Gibson Christopher	Chief Executive Officer	Oct 23 '25	Sale	5.70	100,000	570,000	954,229	Oct 24 06:49 PM
Gibson Christopher	Officer	Oct 23 '25	Proposed Sale	5.70	100,000	570,000		Oct 23 10:37 AM
Gibson Christopher	Chief Executive Officer	Oct 10 '25	Sale	6.04	100,000	604,000	974,229	Oct 10 06:03 PM
Gibson Christopher	Officer	Oct 10 '25	Proposed Sale	6.04	100,000	604,000		Oct 10 10:24 AM
Gibson Christopher	Chief Executive Officer	Sep 25 '25	Sale	4.76	100,000	476,000	954,229	Sep 26 06:32 PM
Gibson Christopher	Officer	Sep 25 '25	Proposed Sale	4.76	100,000	476,000		Sep 25 09:49 AM
Gibson Christopher	Chief Executive Officer	Sep 10 '25	Sale	4.71	100,000	471,000	974,229	Sep 12 04:24 PM
Gibson Christopher	Officer	Sep 10 '25	Proposed Sale	4.71	100,000	471,000		Sep 10 11:10 AM
Gibson Christopher	Chief Executive Officer	Aug 26 '25	Sale	4.84	100,000	484,000	954,229	Aug 28 08:00 PM
Gibson Christopher	Officer	Aug 26 '25	Proposed Sale	4.84	100,000	484,000		Aug 26 10:03 AM
Khan Najat	Chief R&D Commercial Officer	Aug 18 '25	Sale	5.52	36,599	202,173	668,197	Aug 19 06:22 PM
Khan Najat	Officer	Aug 18 '25	Proposed Sale	5.52	36,599	202,169		Aug 18 03:18 PM
Gibson Christopher	Chief Executive Officer	Aug 11 '25	Sale	5.28	500,300	2,641,584	1,004,619	Aug 13 09:03 PM
Gibson Christopher	Chief Executive Officer	Aug 11 '25	Sale	5.28	117,875	622,380	0	Aug 13 09:03 PM
Gibson Christopher	Officer	Aug 11 '25	Proposed Sale	5.28	617,875	3,262,380		Aug 11 03:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RXRX

Recursion Pharmaceuticals Inc

Upgrade your Finviz experience